Functional characterization and drug response of freshly established patient-derived tumor models with cpg island methylator phenotype

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Maletzki, Claudia ^a   Huehns, Maja ^a   Knapp, Patrick ^a   Waukosin, Nancy ^a   Klar, Ernst ^a   Prall, Friedrich ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AZACITIDINE; B RAF KINASE; CA 19-9 ANTIGEN; CISPLATIN; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; K RAS PROTEIN; NILOTINIB; OXALIPLATIN; PACLITAXEL; PROTEIN P53; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CELL STRUCTURE; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND METHYLATOR PHENOTYPE; CYTOKINE RELEASE; DNA FINGERPRINTING; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MOUSE; MUTANT; NONHUMAN; ONCOGENE K RAS; PERSONALIZED MEDICINE; PIK3CA GENE; TUMOR SUPPRESSOR GENE; WILD TYPE; CARCINOMA; COLORECTAL NEOPLASMS; CPG ISLAND; DNA METHYLATION; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; PATHOLOGY; PHENOTYPE; PRIMARY CELL CULTURE;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPITHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PRECISION MEDICINE; PRIMARY CELL CULTURE;

EID: 84957057350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143194     Document Type: Article

References (36)

1. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96: 8681-8686. PMID: 10411935
2. Yamamoto E, Suzuki H, Yamano HO, Maruyama R, Nojima M, Kamimae S, et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol. 2012; 181: 1847-1861. doi: 10.1016/j.ajpath.2012.08.007 PMID: 22995252
3. Konda K, Konishi K, Yamochi T, Ito YM, Nozawa H, Tojo M, et al. Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PLoS One. 2014; 9: E103822. doi: 10.1371/journal. pone.0103822 PMID: 25093594
4. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: Past, present and future. Patholog Res Int. 2011; 2011: 902674. doi: 10.4061/2011/902674 PMID: 21559209
5. Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: A systematic review and meta-analysis. Ann Oncol. 2014; 25: 2314-2327. doi: 10.1093/annonc/mdu149 PMID: 24718889
6. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000; 97: 710-715. PMID: 10639144
7. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMPlow) in colorectal cancer: Possible associations with male sex and KRAS mutations. J Mol Diagn. 2006; 8: 582-588. PMID: 17065427
8. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012; 22: 271-282. doi: 10.1101/gr.117523.110 PMID: 21659424
9. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003; 9: 2898-2903. PMID: 12912934
10. Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011; 140: 1174-1181. doi: 10.1053/j.gastro.2010.12.035 PMID: 21185836
11. Moon JW, Lee SK, Lee JO, Kim N, Lee YW, Kim SJ, et al. Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. J Exp Clin Cancer Res. 2014; 33: 4. doi: 10.1186/1756-9966-33-4 PMID: 24393480
12. Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, et al. Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One. 2012; 7: E52485. doi: 10.1371/journal.pone.0052485 PMID: 23300683
13. Maletzki C, Gock M, Randow M, Klar E, Huehns M, Prall F, et al. Establishment and characterization of cell lines from chromosomal instable colorectal cancer. World J Gastroenterol. 2015; 21: 164-176. doi: 10.3748/wjg.v21.i1.164 PMID: 25574089
14. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, Hardcastle JD, et al. Clinicopathological staging for colorectal cancer: An International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). (ICAT). J Gastroenterol Hepatol. 1991; 6: 325-344. PMID: 1912440
15. Ostwald C, Linnebacher M, Weirich V, Prall F. Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol. 2009; 35: 321-327. PMID: 19578746
16. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96. doi: 10.1136/gut.2008.155473 PMID: 18832519
17. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38: 787-93. PMID: 16804544
18. Kaneda A, Yagi K. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci. 2011; 102: 18-24. doi: 10.1111/j.1349-7006.2010.01712.x PMID: 21159060
19. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: Cohort study and literature review. Mol Cancer. 2014; 13: 135. doi: 10.1186/1476-4598-13-135 PMID: 24885062
20. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4: 988-993. PMID: 15573120
21. Rosfjord E, Lucas J, Li G, Gerber HP. Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014; 91: 135-143. doi: 10.1016/j.bcp.2014.06.008 PMID: 24950467
22. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83: 757-766. PMID: 2041050
23. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014; 74: 2377-2384. doi: 10.1158/0008-5472.CAN-13-2971 PMID: 24717177
24. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013 16; 2: E71. doi: 10.1038/oncsis.2013.35 PMID: 24042735
25. Hua VY, Wang WK, Duesberg PH. Dominant transformation by mutated human ras genes in vitro requires more than 100 times higher expression than is observed in cancers. Proc Natl Acad Sci U S A. 1997; 94: 9614-9619. PMID: 9275171
26. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 1994; 54: 5523-5526. PMID: 7923189
27. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2015; 112: 118-123. doi: 10.1073/pnas.1421839112 PMID: 25535351
28. Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 2010; 59: 1163-1171. doi: 10.1007/s00262-010-0841-1 PMID: 20333377
29. Palena C, Hamilton DH, Fernando RI. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012; 8: 713-722. doi: 10.2217/fon.12.59 PMID: 22764769
30. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12: 375-391. PMID: 11544106
31. Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: An update. Oncotarget. 2014; 5: 49-66. PMID: 24393708
32. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATPcompetitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012; 30: 2219-2225. doi: 10.1007/s10637-012-9793-y PMID: 22270257
33. Cai Z, Ke J, He X, Yuan R, Chen Y, Wu X, et al. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer. Ann Surg Oncol. 2014; 21: 179-188. doi: 10.1245/s10434- 013-3146-8 PMID: 23907312
34. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014; 89: 547-556. doi: 10.1002/ajh.23691 PMID: 24729196
35. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: New hope for successful cancer therapy. Anticancer Agents Med Chem. 2009; 9: 66-76. PMID: 19149483
36. Leroy C, Robert B, Simon V, Roche S. The Abl tyrosine kinase inhibitor Nilotinib inhibits invasive properties of colon cancer cells by targeting the discoidin domain receptor 1. Abstract EJC supplements 8, no. 5 (2010).